Arch Biopartners Inc
XTSX:ARCH
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.01
2.49
|
Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ARCH stock under the Base Case scenario is 0.29 CAD. Compared to the current market price of 1.97 CAD, Arch Biopartners Inc is Overvalued by 85%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Arch Biopartners Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ARCH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Arch Biopartners Inc
Balance Sheet Decomposition
Arch Biopartners Inc
Current Assets | 1.5m |
Cash & Short-Term Investments | 44k |
Receivables | 1.5m |
Other Current Assets | 32.2k |
Current Liabilities | 7.6m |
Accounts Payable | 2.7m |
Accrued Liabilities | 116.4k |
Short-Term Debt | 2.2m |
Other Current Liabilities | 2.6m |
Non-Current Liabilities | 500k |
Long-Term Debt | 500k |
Earnings Waterfall
Arch Biopartners Inc
Revenue
|
4.5m
CAD
|
Operating Expenses
|
-10m
CAD
|
Operating Income
|
-5.5m
CAD
|
Other Expenses
|
-620.6k
CAD
|
Net Income
|
-6.1m
CAD
|
Free Cash Flow Analysis
Arch Biopartners Inc
CAD | |
Free Cash Flow | CAD |
ARCH Profitability Score
Profitability Due Diligence
Arch Biopartners Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Arch Biopartners Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
ARCH Solvency Score
Solvency Due Diligence
Arch Biopartners Inc's solvency score is 16/100. The higher the solvency score, the more solvent the company is.
Score
Arch Biopartners Inc's solvency score is 16/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARCH Price Targets Summary
Arch Biopartners Inc
According to Wall Street analysts, the average 1-year price target for ARCH is 3.57 CAD with a low forecast of 3.54 CAD and a high forecast of 3.68 CAD.
Dividends
Current shareholder yield for ARCH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.
Officers
The intrinsic value of one ARCH stock under the Base Case scenario is 0.29 CAD.
Compared to the current market price of 1.97 CAD, Arch Biopartners Inc is Overvalued by 85%.